Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease

Ayako Suzuki, Paul Angulo, James Lymp, Dave Li, Shinji Satomura, Keith Lindor

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Aim: To determine whether serum hyaluronic acid reliably predicts the severity of hepatic fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Methods: We studied 79 patients with histologically confirmed NAFLD. Hyaluronic acid was measured in serum obtained at the time of liver biopsy. Severity of fibrosis was staged based on Brunt's classification. The prediction levels for fibrosis were determined by area under the receiver operating characteristic curve (AUC). Results: The logarithm of serum hyaluronic acid was significantly different among the stages of fibrosis (P<0.0001, analysis of variance) and had a significant positive correlation with the degrees of fibrosis after adjusting for age and serum albumin (partial r = 0.44, P<0.0001). AUCs were 0.67, 0.87, 0.89, and 0.92 for any levels of fibrosis, ≥ moderate fibrosis, ≥ severe fibrosis, and cirrhosis, all of which were significantly higher than 0.5 (P<0.05). The cut-off value of serum hyaluronic acid of 46.1 μg/l was associated with the highest AUC for severe fibrosis, yielding a sensitivity of 85% and a specificity of 80%. The corresponding positive and negative predictive values were 51% and 96%, when assuming prevalence of severe fibrosis in NAFLD patients of 20% at referral centers. Conclusion: Measurement of serum hyaluronic acid is useful to identify NAFLD patients with severe fibrosis.

Original languageEnglish (US)
Pages (from-to)779-786
Number of pages8
JournalLiver International
Volume25
Issue number4
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Hyaluronic Acid
Fibrosis
Biomarkers
Liver
Area Under Curve
Serum
Non-alcoholic Fatty Liver Disease
Serum Albumin
ROC Curve
Analysis of Variance
Referral and Consultation
Biopsy

Keywords

  • Fatty liver
  • Hepatic fibrosis
  • Hyaluronic acid
  • Non-alcoholic
  • Serum marker

ASJC Scopus subject areas

  • Hepatology

Cite this

Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. / Suzuki, Ayako; Angulo, Paul; Lymp, James; Li, Dave; Satomura, Shinji; Lindor, Keith.

In: Liver International, Vol. 25, No. 4, 08.2005, p. 779-786.

Research output: Contribution to journalArticle

Suzuki, Ayako ; Angulo, Paul ; Lymp, James ; Li, Dave ; Satomura, Shinji ; Lindor, Keith. / Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. In: Liver International. 2005 ; Vol. 25, No. 4. pp. 779-786.
@article{7431468fa589400286f68cb660dc3335,
title = "Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease",
abstract = "Aim: To determine whether serum hyaluronic acid reliably predicts the severity of hepatic fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Methods: We studied 79 patients with histologically confirmed NAFLD. Hyaluronic acid was measured in serum obtained at the time of liver biopsy. Severity of fibrosis was staged based on Brunt's classification. The prediction levels for fibrosis were determined by area under the receiver operating characteristic curve (AUC). Results: The logarithm of serum hyaluronic acid was significantly different among the stages of fibrosis (P<0.0001, analysis of variance) and had a significant positive correlation with the degrees of fibrosis after adjusting for age and serum albumin (partial r = 0.44, P<0.0001). AUCs were 0.67, 0.87, 0.89, and 0.92 for any levels of fibrosis, ≥ moderate fibrosis, ≥ severe fibrosis, and cirrhosis, all of which were significantly higher than 0.5 (P<0.05). The cut-off value of serum hyaluronic acid of 46.1 μg/l was associated with the highest AUC for severe fibrosis, yielding a sensitivity of 85{\%} and a specificity of 80{\%}. The corresponding positive and negative predictive values were 51{\%} and 96{\%}, when assuming prevalence of severe fibrosis in NAFLD patients of 20{\%} at referral centers. Conclusion: Measurement of serum hyaluronic acid is useful to identify NAFLD patients with severe fibrosis.",
keywords = "Fatty liver, Hepatic fibrosis, Hyaluronic acid, Non-alcoholic, Serum marker",
author = "Ayako Suzuki and Paul Angulo and James Lymp and Dave Li and Shinji Satomura and Keith Lindor",
year = "2005",
month = "8",
doi = "10.1111/j.1478-3231.2005.01064.x",
language = "English (US)",
volume = "25",
pages = "779--786",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease

AU - Suzuki, Ayako

AU - Angulo, Paul

AU - Lymp, James

AU - Li, Dave

AU - Satomura, Shinji

AU - Lindor, Keith

PY - 2005/8

Y1 - 2005/8

N2 - Aim: To determine whether serum hyaluronic acid reliably predicts the severity of hepatic fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Methods: We studied 79 patients with histologically confirmed NAFLD. Hyaluronic acid was measured in serum obtained at the time of liver biopsy. Severity of fibrosis was staged based on Brunt's classification. The prediction levels for fibrosis were determined by area under the receiver operating characteristic curve (AUC). Results: The logarithm of serum hyaluronic acid was significantly different among the stages of fibrosis (P<0.0001, analysis of variance) and had a significant positive correlation with the degrees of fibrosis after adjusting for age and serum albumin (partial r = 0.44, P<0.0001). AUCs were 0.67, 0.87, 0.89, and 0.92 for any levels of fibrosis, ≥ moderate fibrosis, ≥ severe fibrosis, and cirrhosis, all of which were significantly higher than 0.5 (P<0.05). The cut-off value of serum hyaluronic acid of 46.1 μg/l was associated with the highest AUC for severe fibrosis, yielding a sensitivity of 85% and a specificity of 80%. The corresponding positive and negative predictive values were 51% and 96%, when assuming prevalence of severe fibrosis in NAFLD patients of 20% at referral centers. Conclusion: Measurement of serum hyaluronic acid is useful to identify NAFLD patients with severe fibrosis.

AB - Aim: To determine whether serum hyaluronic acid reliably predicts the severity of hepatic fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Methods: We studied 79 patients with histologically confirmed NAFLD. Hyaluronic acid was measured in serum obtained at the time of liver biopsy. Severity of fibrosis was staged based on Brunt's classification. The prediction levels for fibrosis were determined by area under the receiver operating characteristic curve (AUC). Results: The logarithm of serum hyaluronic acid was significantly different among the stages of fibrosis (P<0.0001, analysis of variance) and had a significant positive correlation with the degrees of fibrosis after adjusting for age and serum albumin (partial r = 0.44, P<0.0001). AUCs were 0.67, 0.87, 0.89, and 0.92 for any levels of fibrosis, ≥ moderate fibrosis, ≥ severe fibrosis, and cirrhosis, all of which were significantly higher than 0.5 (P<0.05). The cut-off value of serum hyaluronic acid of 46.1 μg/l was associated with the highest AUC for severe fibrosis, yielding a sensitivity of 85% and a specificity of 80%. The corresponding positive and negative predictive values were 51% and 96%, when assuming prevalence of severe fibrosis in NAFLD patients of 20% at referral centers. Conclusion: Measurement of serum hyaluronic acid is useful to identify NAFLD patients with severe fibrosis.

KW - Fatty liver

KW - Hepatic fibrosis

KW - Hyaluronic acid

KW - Non-alcoholic

KW - Serum marker

UR - http://www.scopus.com/inward/record.url?scp=22844448952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22844448952&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2005.01064.x

DO - 10.1111/j.1478-3231.2005.01064.x

M3 - Article

C2 - 15998429

AN - SCOPUS:22844448952

VL - 25

SP - 779

EP - 786

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 4

ER -